Le Lézard
Classified in: Ebola virus, Health
Subject: SLS

Toll Like Receptor 3 Pipeline Therapeutics Development Review H1 2017


PUNE, India, June 21, 2017 /PRNewswire-iReach/ -- Toll Like Receptor 3 Pipeline Therapeutics Development Review H1 2017 Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development: Hemispherx Biopharma Inc, Innate Pharma SA,  Johnson & Johnson, MultiCell Technologies Inc, Oncovir Inc, RMB-Research GmbH.

Purchase This 69 Pages Report including 23 Tables and 9 Figure At http://www.reportsnreports.com/purchase.aspx?name=1057863

Toll Like Receptor 3 (CD283 or TLR3) Drug Profiles Discussed In Report: Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases, CNTO-3157, CU-CPT4a, Drugs to Activate TLR3 for Atherosclerosis, IPH-33, MCT-465, Oligonucleotide to Agonize TLR3 for OncologyP-7, PEP-0202, Poly-ICLC, PrEP-001, rintatolimod, Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome

Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Infectious Disease, Respiratory, Immunology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Other Diseases which include indications Breast Cancer, Asthma, Autoimmune Disorders, Chronic Inflammation, Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Acute Inflammation, Atherosclerosis, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Obstructive Pulmonary Disease (COPD), Colitis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Foot Ulcers, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Peritoneal Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Venous Leg Ulcers (Crural ulcer), West Nile Virus Infections, Wounds and Zika Virus Infections.

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3) and reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources. This Research report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages  also features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and all their major and minor projects  are reviewed in this report.The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics.

About Us:

Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries

Contact Us:

Ritesh Tiwari

2nd Floor, Metropole,

Bund Garden Road,

Pune ? 411001,

India.

Tel: + 1 888 391 5441

E-mail: [email protected]

Media Contact: Ritesh Tiwari, ReportsnReports, +1-888-391-5441, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE ReportsnReports.com


These press releases may also interest you

21 mar 2019
The "Europe Welding Equipment Market-Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Welding is one of the critical processes employed in the manufacturing...

21 mar 2019
Inovio Pharmaceuticals, Inc. announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the...

20 mar 2019
Merck , known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to extend the research phase of the companies' broad, strategic collaboration...

20 mar 2019
The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Monday, 29 April 2019 at 3:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden. RIGHT TO PARTICIPATE AND NOTICE Shareholders who wish to...

20 mar 2019
The Oslo Business for Peace Award is given to inspiring business leaders who have put society first. 2019's winners are: Dr Agbor Ashumanyi Ako, medical director of GiftedMom, Alice Laugher, CEO of Committed to...

19 mar 2019
The evolving competitive market has made it essential for the telecommunication industry to rethink traditional ways of doing business in terms of the impact on business models, service portfolios and technical architectures. Digital business support...



News published on and distributed by: